Capital Fund Management S.A. Increases Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Capital Fund Management S.A. raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 147.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,136 shares of the company's stock after buying an additional 118,604 shares during the quarter. Capital Fund Management S.A. owned about 0.23% of Progyny worth $3,435,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Signaturefd LLC increased its holdings in shares of Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after acquiring an additional 1,526 shares during the period. Caitlin John LLC boosted its position in shares of Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Progyny in the fourth quarter valued at about $74,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several recent analyst reports. Bank of America boosted their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. Finally, JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded up $0.04 during trading hours on Friday, reaching $21.44. The stock had a trading volume of 1,236,518 shares, compared to its average volume of 1,741,105. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 36.97, a P/E/G ratio of 2.39 and a beta of 1.33. The firm's 50 day moving average is $21.94 and its 200-day moving average is $18.84. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $33.84.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.